Eli Lilly’s Tirzepatide Approved in China for Weight Loss Management Amid Growing Obesity Concerns

Eli Lilly, Tirzepatide, Weight Loss, China, Obesity, Novo Nordisk, GLP-1 Agonists, Diabetes, Mounjaro, Zepbound, Semaglutide, Wegovy

Lilly’s Tirzepatide Wins NICE Endorsement for Obesity Treatment with BMI and Weight Loss Conditions

Lilly, tirzepatide, NICE endorsement, obesity treatment, BMI, weight loss, Zepbound, Mounjaro, GLP-1 receptor agonist